It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Built on a strong foundation
Built on a strong foundation

With the launch of ZIEXTENZO® (pegfilgrastim-bmez), Sandoz became the first to deliver a short-acting and long-acting G-CSF biosimilar.2,3

Sandoz biosimilar manufacturing

The value
of biosimilars

The role of biosimilars
in oncology

Sandoz biosimilar savings

Sandoz biosimilar

Bringing savings to the healthcare system

Same safety and efficacy profile as Neulasta

Same safety and
efficacy profile
as Neulasta® 

Proven therapeutic and bioequivalence

Eligible and commercially insured patients can enroll by phone or online.

patients pay $0

Eligible, commercially insured patients can enroll online

*Based on market share analysis as of May 2023.
Eligibility Requirements: Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZIEXTENZO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.

G-CSF=granulocyte colony-stimulating factor.

Neulasta is a registered trademark of Amgen Inc.

References1. Data on file. ZARXIO and ZIEXTENZO Market Share Analysis. May 2023. 2. ZARXIO Prescribing Information. Sandoz Inc. September 2022. 3. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021. 4. Data on file. Filgrastim Net Sales Analysis Model. Sandoz Inc. January 2023. 5. Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12(11):1359-1367. 6. Blackwell K, Donskih R, Jones MC, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21(7):789-794. 7. Data on file. Clinical Study Report of Study LA-EP06-104. Sandoz Inc. February 2019.